<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="80383">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02058940</url>
  </required_header>
  <id_info>
    <org_study_id>13-1391</org_study_id>
    <secondary_id>Astra Zeneca Pharmaceuticals</secondary_id>
    <secondary_id>Medtronic MiniMed, Inc</secondary_id>
    <nct_id>NCT02058940</nct_id>
  </id_info>
  <brief_title>Intravenous Exenatide in Patients With Acute Brain Injury</brief_title>
  <official_title>Intravenous Exenatide Infusion in Critically Ill Patients With Acute Brain Injury</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of North Carolina, Chapel Hill</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Medtronic</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of North Carolina, Chapel Hill</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the feasibility of exenatide infusion for the
      treatment of high blood sugars following acute brain injury.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>August 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility defined as the proportion of patients 1) experiencing severe hypoglycemia (&lt;40 mg/dL); 2) achieving glucose measurements within goal (110-180 mg/dL); and 3) experiencing nausea requiring discontinuation of exenatide therapy</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean glucose concentration during exenatide infusion</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of glucose measurements within goal (110-180 mg/dL)/total number of glucose measurements</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean time to reach glucose measurements within goal (110-180 mg/dL)</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glycemic variability defined as the standard deviation of glucose</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from continuous blood glucose monitoring starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean insulin use (units/kg body weight)</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from number of insulin units administered over 48 hours starting at infusion initiation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects requiring rescue insulin infusion protocol</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypoglycemic episodes (&lt;80 mg/dL)/total number of glucose measurements</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of subjects with &gt;1 episode of hypoglycemia (&lt;80 mg/dL)/total number of subjects</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from hourly blood glucose samples starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients experiencing metabolic crisis defined as cerebral microdialysate glucose concentration &lt;0.7 mmol/L in combination with lactate pyruvate ratio &gt;40</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from hourly microdialysis samples starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean daily intracranial and cerebral perfusion pressures</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from hourly measurements starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of hypotensive episodes (SBP&lt;100 mmHg)/total number of blood pressure measurements</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from hourly measurements starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients experiencing serious adverse events</measure>
    <time_frame>30 days</time_frame>
    <description>death, life-threatening event, prolonged hospitalization, disability or incapacity, congenital anomaly or birth defect, or important non-life threatening medical event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics of exenatide infusion defined as the correlation of exenatide concentrations with creatinine clearance</measure>
    <time_frame>Over 48 hours from infusion initiation</time_frame>
    <description>Calculated from exenatide concentrations and urine creatinine measurements starting at infusion initiation over 48 hours</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Brain Injuries</condition>
  <arm_group>
    <arm_group_label>Exenatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Exenatide</intervention_name>
    <description>50 ng/min IV for 30 minutes, then start 25 ng/min IV for a maximum duration of 48 hours</description>
    <arm_group_label>Exenatide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults ≥18 years

          -  Acute brain injury resulting in admission to the Neurosciences Intensive Care Unit
             for an anticipated length of stay &gt;48 hours

          -  Two Blood glucose concentrations &gt; 150 mg/dL and ≤300 mg/dL

          -  Informed consent obtained via proxy

        Exclusion Criteria:

          -  Pregnant (verified by urine or serum pregnancy test within 24 hours of initiation of
             infusion) or lactating females

          -  Type 1 diabetes mellitus

          -  History of pancreatitis or risk factors for acute pancreatitis (i.e ethanol abuse,
             gall stones)

          -  Renal insufficiency defined as creatinine clearance (CrCL) &lt; 45 mL/min

          -  Known history of gastroparesis

          -  History of surgery on stomach, esophagus or duodenum

          -  Diabetic Ketoacidosis or Hyperosmolar Hyperglycemic Nonketotic Syndrome

          -  Concurrent steroid use or planned post-operative steroid use

          -  History of organ transplantation

          -  Brain death or suspected imminent brain death within the next 72 hours

          -  Refractory intracranial hypertension defined as intracranial pressure (ICP) &gt; 25 mmHg
             for greater than 15 minutes and refractory to medical intervention

          -  Currently enrolled in another investigational drug or device protocol

          -  Insulin infusion within 3 hours of study drug administration or confirmed long acting
             insulin or sulfonylurea use prior to admission within 24 hours of study drug
             administration

          -  Known allergy to exenatide
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicole R. Pinelli, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of North Carolina, Chapel Hill</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nicole R. Pinelli, PharmD</last_name>
    <phone>919-962-1641</phone>
    <email>nickipinelli@unc.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of North Carolina; UNC Medical Center</name>
      <address>
        <city>Chapel Hill</city>
        <state>North Carolina</state>
        <zip>27599</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole R. Pinelli, PharmD</last_name>
      <phone>919-962-1641</phone>
      <email>nickipinelli@unc.edu</email>
    </contact>
    <investigator>
      <last_name>Nicole R. Pinelli, PharmD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <lastchanged_date>May 11, 2016</lastchanged_date>
  <firstreceived_date>February 6, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Brain Injuries</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
